Edition:
United Kingdom

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

42.30USD
6:12pm GMT
Change (% chg)

$1.05 (+2.55%)
Prev Close
$41.25
Open
$40.70
Day's High
$43.05
Day's Low
$40.50
Volume
82,011
Avg. Vol
203,925
52-wk High
$43.35
52-wk Low
$8.55

Select another date:

Wed, Jan 31 2018

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME

BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln

* ZOGENIX INC - MAY ISSUE AND SELL SHARES OF COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION Source text: (http://bit.ly/2kHM2Eb) Further company coverage:

BRIEF-Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008

* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME

BRIEF-Zogenix posts Q3 loss of $1.68 per share

* Zogenix provides corporate update and reports third quarter 2017 financial results

BRIEF-Zogenix announces closing of public offering of common stock

* Zogenix announces closing of public offering of common stock, including full exercise of underwriters’ option to purchase additional shares Source text for Eikon: Further company coverage:

BRIEF-Zogenix files for potential mixed shelf filing; size not disclosed - SEC filing‍​

* Files for potential mixed shelf filing; size not disclosed - SEC filing‍​ Source text : (http://bit.ly/2xOgvG9) Further company coverage:

Zogenix stock soars on epilepsy drug trial success

Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .

UPDATE 3-Zogenix stock soars on epilepsy drug trial success

* Analyst expects drug to become standard in Dravet treatment

BRIEF-Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome

* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome

Zogenix epilepsy drug meets main goal in late-stage trial

Sept 29 Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.

Select another date: